Deliver Your News to the World

New Preoperative Treatment Combination Safe for Pancreatic Cancer Patients Undergoing Surgery, UPCI Study Finds


CHICAGO , June 2008 — Treating pancreatic cancer with a combination of chemotherapy, biotherapy and radiotherapy prior to surgery is safe and may be beneficial for patients, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

In a preliminary study, physicians from the Pancreatic Cancer Center of the University of Pittsburgh Medical Center (UPMC) Cancer Centers examined the safety of combining gemcitabine with bevacizumab and radiotherapy in patients with operable pancreatic cancer. In the study, 14 patients with potentially operable tumors completed the treatment regimen. Following treatment, 10 of the patients were considered eligible for surgery. The incidence of serious adverse events following surgery was not increased in these patients, and several demonstrated significant shrinkage of their tumors before surgery.

“The results from the first phase of this two-phase trial are encouraging,” said A. James Moser, M.D., lead author of the study, co-director of the Pancreatic Cancer Center and assistant professor of surgery at the University of Pittsburgh School of Medicine. “Patients who receive surgery for pancreatic cancer tend to have better outcomes than those who don’t, and this treatment allows us to reduce the tumor size prior to surgery.”

Given the evidence of tumor-shrinkage from the initial treatment, Dr. Moser and his colleagues are enrolling patients for the second stage of the study to further evaluate the effectiveness of the treatment.

Each year, about 33,000 individuals in the U.S. are diagnosed with pancreatic cancer. It is difficult to diagnose early because symptoms are both rare and varied, and often don’t occur until the disease has progressed. Because of this, patients diagnosed with pancreatic cancer typically have a poor prognosis, underscoring the importance of new treatment options.

Co-authors of the study include H.J. Zeh, M.D.; R.K. Ramanathan, M.D.; A.M. Krasinskas, M.D.; M.E. Tublin, M.D.; R.P. Smith; F. Stover; K.K. Lee, Ph.D.; S.J. Hughes, M.D.; and D.L. Bartlett, M.D., all of UPMC Cancer Centers. The study is sponsored by Genentech.

The study is published as abstract number 4631 in the 2008 ASCO Annual Meeting Proceedings.

Founded in 1984, the University of Pittsburgh Cancer Institute became a National Cancer Institute (NCI)-designated Comprehensive Cancer Center in record time (by 1990). UPCI, the only cancer center in western Pennsylvania with this elite designation, serves the region’s population of more than six million. Presently, UPCI receives a total of $154 million in research grants and is ranked 10th in funding from the NCI.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.